Live Oak Health Sciences Fund (LOGSX)
23.10
+0.08
(+0.35%)
USD |
May 08 2026
Returns Chart
Key Stats
| Net Expense Ratio | Total Assets Under Management | Weighted Average Dividend Yield | Turnover Ratio (Generic) |
|---|---|---|---|
| 1.04% | 49.01M | 1.15% | 24.00% |
| 1 Year Fund Level Flows | 1 Year Total Returns (Daily) | Annualized Total Returns Since Inception (Daily) | Max Drawdown (Since Inception) |
| -6.769M | 16.99% |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing at least 80% of its net assets in common stocks of companies engaged in the research, development, production or distribution of products or services related to health care, medicine, or the life sciences. The Fund is non-diversified and will only hold a few stocks. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Oak Associates Funds |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Net Fund Flows Versus Peer Group
1 Month
% Rank:
15
-544.14M
Peer Group Low
637.08M
Peer Group High
1 Year
% Rank:
36
-6.769M
-2.461B
Peer Group Low
1.069B
Peer Group High
3 Months
% Rank:
33
-929.88M
Peer Group Low
166.12M
Peer Group High
3 Years
% Rank:
29
-6.931B
Peer Group Low
600.89M
Peer Group High
6 Months
% Rank:
40
-1.002B
Peer Group Low
1.136B
Peer Group High
5 Years
% Rank:
30
-8.512B
Peer Group Low
3.739B
Peer Group High
YTD
% Rank:
37
-599.30M
Peer Group Low
1.055B
Peer Group High
10 Years
% Rank:
37
-12.96B
Peer Group Low
5.580B
Peer Group High
Date Unavailable
Risk
Performance Versus Peer Group
Annual Total Returns Versus Peers
As of May 08, 2026.
Asset Allocation
As of March 31, 2026.
| Type | % Net |
|---|---|
| Cash | 3.07% |
| Stock | 96.81% |
| Bond | 0.00% |
| Convertible | 0.00% |
| Preferred | 0.00% |
| Other | 0.12% |
Top 10 Holdings
| Name | % Weight | Price | % Change |
|---|---|---|---|
| United Therapeutics Corp. | 6.54% | 564.97 | -0.74% |
| Cardinal Health, Inc. | 6.01% | 183.67 | -0.87% |
| McKesson Corp. | 5.12% | 735.88 | -2.50% |
| Novartis AG | 5.10% | 145.99 | 0.41% |
| Cencora, Inc. | 5.02% | 261.21 | 2.17% |
| Regeneron Pharmaceuticals, Inc. | 5.01% | 714.67 | 0.79% |
| Amgen, Inc. | 4.95% | 331.64 | 0.77% |
| Jazz Pharmaceuticals Plc | 4.82% | 225.73 | -0.54% |
| Exelixis, Inc. | 4.47% | 48.16 | 4.22% |
| Johnson & Johnson | 4.02% | 221.24 | -0.57% |
Fees & Availability
| Fees | |
| Actual 12B-1 Fee | -- |
| Actual Management Fee | 0.74% |
| Administration Fee | 28.32K% |
| Maximum Front Load | -- |
| Maximum Deferred Load | -- |
| Maximum Redemption Fee | -- |
| General Availability | |
| Available for Insurance Product | No |
| Available for RRSP | No |
| Purchase Details | |
| Open to New Investors |
|
| Minimum Initial Investment | 2000.00 None |
| Minimum Subsequent Investment | 25.00 None |
Basic Info
| Investment Strategy | |
| The Fund seeks long-term capital growth by investing at least 80% of its net assets in common stocks of companies engaged in the research, development, production or distribution of products or services related to health care, medicine, or the life sciences. The Fund is non-diversified and will only hold a few stocks. |
| General | |
| Security Type | Mutual Fund |
| Equity Style | Multi Cap Core |
| Broad Asset Class | Sector Equity |
| Broad Category | Equity |
| Global Peer Group | Equity Sector Healthcare |
| Peer Group | Health/Biotechnology Funds |
| Global Macro | Equity Industry Sector |
| US Macro | Sector Equity Funds |
| YCharts Categorization | -- |
| YCharts Benchmark | -- |
| Prospectus Objective | Health/Biotechnology Funds |
| Fund Owner Firm Name | Oak Associates Funds |
| Broad Asset Class Benchmark Index | |
| ^MSWNTR | 100.0% |
Fundamentals
| General | |
| Distribution Yield | -- |
| Dividend Yield TTM (5-7-26) | 0.10% |
| 30-Day SEC Yield | -- |
| 7-Day SEC Yield | -- |
| Number of Holdings | 29 |
| Stock | |
| Weighted Average PE Ratio | 25.22 |
| Weighted Average Price to Sales Ratio | 4.503 |
| Weighted Average Price to Book Ratio | 8.155 |
| Weighted Median ROE | 37.82% |
| Weighted Median ROA | 11.21% |
| ROI (TTM) | 17.44% |
| Return on Investment (TTM) | 17.44% |
| Earning Yield | 0.0449 |
| LT Debt / Shareholders Equity | 1.392 |
| Number of Equity Holdings | 27 |
As of March 31, 2026
Growth Metrics
| EPS Growth (1Y) | 39.29% |
| EPS Growth (3Y) | 26.97% |
| EPS Growth (5Y) | 18.19% |
| Sales Growth (1Y) | 9.00% |
| Sales Growth (3Y) | 10.87% |
| Sales Growth (5Y) | 11.62% |
| Sales per Share Growth (1Y) | 11.94% |
| Sales per Share Growth (3Y) | 13.26% |
| Operating Cash Flow - Growth Rate (3Y) | 14.40% |
As of March 31, 2026
Fund Details
| Key Dates | |
| Inception Date | 6/29/2001 |
| Last Annual Report Date | 10/31/2025 |
| Last Prospectus Date | 2/28/2026 |
| Attributes | |
| Index Fund | -- |
| Inverse Fund | No |
| Leveraged Fund | -- |
| Fund of Funds | No |
| Currency Hedged Fund | -- |
| Socially Responsible Fund | No |
Top Portfolio Holders
| Name | % Weight |
|---|---|
| Portfolio A | 5.00% |
| Portfolio B | 3.50% |
| Portfolio C | 2.25% |
Excel Add-In Codes
| Name: =YCI("M:LOGSX", "name") |
| Broad Asset Class: =YCI("M:LOGSX", "broad_asset_class") |
| Broad Category: =YCI("M:LOGSX", "broad_category_group") |
| Prospectus Objective: =YCI("M:LOGSX", "prospectus_objective") |
| To find the codes for any of our securities and financial metrics, see our Complete Excel Reference. |